Login or sign up
For business

Deciphera pharmaceuticals

4.0· 11 reviews
Average ratingGreat
4.0/ 5

Based on 11 reviews

527%
445%
327%
20%
10%
Jeffrey Jacobs
Reviews 1

I recently started working for a pharmaceutical company and I'm really enjoying the experience. The environment is positive and everyone is friendly and helpful. The projects I'm working on are interesting and I feel like I'm making a difference. Highly recommended!

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About Deciphera pharmaceuticals

At Deciphera, we remain steadfast in our mission to improve the lives of people living with cancer - and that passion for making a difference extends to the patient groups and communities in which we live and work.

Deciphera Pharmaceuticals: Revolutionizing Cancer Treatment

Deciphera Pharmaceuticals is a biopharmaceutical company that is dedicated to discovering, developing, and commercializing innovative medicines to improve the lives of people living with cancer. The company was founded in 2003 and has since been at the forefront of cancer research, developing novel therapies that target specific molecular pathways involved in tumor growth.

At Deciphera, the mission is clear - to make a difference in the lives of patients suffering from cancer. The team at Deciphera works tirelessly towards this goal by leveraging their expertise in drug discovery and development to create new treatments for various types of cancers.

The company's flagship product is Qinlock (ripretinib), an oral kinase inhibitor approved by the FDA for treating advanced gastrointestinal stromal tumors (GISTs). Qinlock has shown remarkable efficacy in clinical trials, demonstrating significant improvement in progression-free survival compared to placebo.

In addition to Qinlock, Deciphera has a robust pipeline of other promising drugs under development. These include DCC-3014, a selective inhibitor of colony-stimulating factor 1 receptor (CSF1R) currently being evaluated for its potential use as an immunotherapy agent; DCC-3116, an investigational drug designed to target solid tumors with mutations or amplifications in fibroblast growth factor receptor 2 (FGFR2); and DCC-2618, another kinase inhibitor being developed for treating GISTs and other solid tumors.

What sets Deciphera apart from other pharmaceutical companies is its commitment not only towards developing effective treatments but also towards making them accessible to patients who need them most. The company works closely with patient groups and communities worldwide to ensure that their products are affordable and available where they are needed most.

Moreover, Deciphera's dedication towards sustainability extends beyond just creating life-saving drugs. The company takes pride in minimizing its environmental impact through responsible manufacturing practices while also supporting local communities through various initiatives such as volunteering programs and charitable donations.

In conclusion, Deciphera Pharmaceuticals stands out as one of the leading players in cancer research today. With its innovative approach towards drug discovery coupled with its unwavering commitment towards improving patient outcomes worldwide - it's no surprise why this biopharmaceutical giant continues to be at the forefront of cutting-edge oncology research.

Address
200 smith street
Categories
Pharmaceuticals